Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Provided By GlobeNewswire
Last update: Nov 21, 2025
– Company to Receive $90 Million Total Payment –
– Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL –
Read more at globenewswire.com
